The most important reason for therapy failure in pediatric acute myeloid leukemia (AML) is
relapse. In order to identify miRNAs that contribute to the clonal evolution towards relapse in …

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology
as well as outcome. In this study, we investigated whether known biological subgroups of …

Purpose Children with acute myeloid leukemia (AML) whose disease is refractory to
standard induction chemotherapy therapy or who experience relapse after initial response …

Background miRNAs regulate gene expression, and thus play an important role in critical
cellular processes. Aberrant miRNA expression patterns have been found in various types of …

Novel therapeutic strategies are needed for paediatric patients affected by Acute Myeloid
Leukaemia (AML), particularly for those at high-risk for relapse. MicroRNAs (miRs) have …

MicroRNAs (miRNAs) control the expression of protein-coding genes in normal
hematopoietic cells and, consequently, aberrant expression may contribute to …

Childhood acute lymphoblastic leukemia (ALL) is a genetically and prognostically
heterogeneous malignancy with a mortality rate of 20%[1]. The identification of novel …

MicroRNAs (miRNAs) play a pivotal role in the regulation of hematopoiesis and
development of leukemia. Great interest emerged in modulating miRNA expression for …

Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies
with variable response to treatment. AMLs bearing MLL (mixed lineage leukemia) …

MicroRNAs (miRNAs) are postulated to be important regulators in cancers. Here, we report a
genome-wide miRNA expression analysis in 52 acute myeloid leukemia (AML) samples with …